CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities:
Net loss	$ (2,014)	$ (654)
Adjustments to reconcile net loss to net cash provided by operating activities, net of acquisition:
Depreciation and amortization	1,673	1,324
Amortization finance lease	75
Change on operating lease	81
Employee stock compensation expense	204	124
Gain on disposal of property and equipment		(3)
Unrealized foreign currency gains	5	(136)
Changes in operating assets and liabilities:
Accounts receivable	(1,873)	266
Inventories	(109)	79
Income tax accruals	102	29
Prepaid expenses and other assets	(723)	(227)
Accounts payable	(577)	(145)
Accrued expenses	(422)	(329)
Customer advances	3,791	583
Net cash provided by operating activities	213	911
Investing activities:
Capital expenditures	(4,000)
Cash paid in acquisition	(3,351)	(2,218)
Net cash used in investing activities	(7,351)	(2,218)
Financing activities:
Payments on finance lease liability	(79)
Payments of long-term debt	(603)	(451)
Payments of debt issuance costs	(111)	(22)
Payments on revolving line of credit	(22,711)	(11,505)
Borrowings on revolving line of credit	24,263	11,914
Borrowings on construction loan	1,089	908
Borrowings on equipment loan		285
Borrowings on capex line of credit	1,329
Payments of capital lease obligations		(76)
Borrowings on long-term loan	3,533
Proceeds from exercise of stock options	20	1
Net cash provided by financing activities	6,730	1,054
Net decrease in cash and cash equivalents	(408)	(253)
Cash and cash equivalents at beginning of period	606	773
Cash and cash equivalents at end of period	198	520
Supplemental disclosure of cash flow information:
Cash paid for interest	494	$ 225
Preclinical Research Services acquisition:
Assets acquired	6,435
Liabilities assumed	(1,302)
Common shares issued	(1,133)
Cash paid	$ 4,000